PA5-20979
antibody from Invitrogen Antibodies
Targeting: ZEB1
AREB6, BZP, FECD6, NIL-2-A, PPCD3, TCF8, ZEB, Zfhep, Zfhx1a
Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [3]
- Immunocytochemistry [5]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-20979 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ZEB1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A suggested positive control is Hela cell lysate. PA5-20979 can be used with blocking peptide PEP-1093.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- 4° C
Submitted references Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells.
miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy.
Aedo-Aguilera V, Carrillo-Beltrán D, Calaf GM, Muñoz JP, Guerrero N, Osorio JC, Tapia JC, León O, Contreras HR, Aguayo F
Oncology reports 2019 Nov;42(5):2139-2148
Oncology reports 2019 Nov;42(5):2139-2148
miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy.
Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM
Cancers 2018 Aug 25;10(9)
Cancers 2018 Aug 25;10(9)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of HeLa cell lysate using a ZEB1 polyclonal antibody (Product # PA5-20979) at 1 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of ZEB1 in HeLa cell lysate with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 1 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot was performed using Anti-ZEB1 Polyclonal Antibody (Product # PA5-20979) and a 124 kDa band corresponding to ZEB1 was observed across all cell lines and decreased upon Doxorubicin treatment in Hep G2. Whole cell extracts (30 µg lysate) of HeLa (Lane 1), Hep G2 (Lane 2), Hep G2 treated with Doxorubicin (1mM for 24 hr) (Lane 3), MCF-7 (Lane 4) were electrophoresed using NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1ug/ml) and detected by Goat anti-Rabbit IgG (H+L), Superclonal™ Recombinant Secondary Antibody, HRP conjugate (Product # A27036, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry staining of HeLa cells using a ZEB1 polyclonal antibody (Product # PA5-20979) at a 20 µg/mL dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of HeLa cells using a ZEB1 polyclonal antibody (Product # PA5-20979) at a 20 µg/mL dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry of ZEB1 in HeLa cells with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 20 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry of ZEB1 in K562 cells with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 2.5 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence of ZEB1 in Hela cells with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 20 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry of ZEB1 in human liver tissue with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 5 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 miR-205-NPs inhibits EMT signaling and sensitizes Dtxl treatment in PrCa cells. ( A ) miR-205-NPs treatment suppresses the migratory ability of C4-2 and PC-3 cells in presence/absence of the drug through Boyden chamber study. Images were captured at 20x magnification. Transwell assay with matrigel was performed to detect invasion activity of PrCa cells transfected with miR-205. Docetaxel treatments at 5 nM concentration. Scale bar: 200 um. ( B ) Protein profiling studies of Control, miR-205 transfected and miR-205-NPs treated PrCa cells for 24 h for EMT signaling. Note: miR-205-L or miR-205-Lipo represents same and indicates to miR-205 transfected with lipofectamine.